SIR-Spheres® Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union, Argentina, Brazil, Canada and several countries in Asia, such as India, Indonesia, Malaysia, Myanmar, Singapore and South Korea.
In Taiwan SIR-Spheres Y-90 resin microspheres are approved for the treatment of metastatic liver tumors from primary colorectal cancer which are uncontrolled by IHAC and/or Chemotherapy. SIR-Spheres are unsuitable for use in patients with poor liver function such as those affected by Hepatitis B or suffering from hyperbilirubinemia. SIR-Spheres are also approved for use in the treatment of hepatocellular carcinoma in patients who are ineligible for ablation or resection.
In the United States, SIR-Spheres Y-90 resin microspheres received Premarket Approval (PMA) from the FDA and are indicated for the treatment of non-resectable metastatic liver tumors from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine.
Disclaimer: Content on SIR-Spheres Y-90 resin microspheres is not intended for users in markets that do not have authorization for use.